Recognising the vital role of patients in medical and scientific research, the Future Science Group (FSG) has published a new style of article – a Plain Language Summary of Publication, the first of its kind for FSG. The article, published in Future Oncology, provides a summary of a recently published paper and has been written and designed specifically to be read by patient and non-specialist audiences to help them to understand the research presented.
The article entitled ‘ENLIVEN study: pexidartinib for tenosynovial giant cell tumor (TGCT)’, written by Dr William Tap of Memorial Sloan Kettering Cancer Center, provides a summary of a clinical trial originally published in The Lancet.
The full Plain Language Summary of Publication is available free to read at https://www.futuremedicine.com/doi/10.2217/FON-2020-0307.
Brought to you by Scope e-Knowledge Center, a trusted global partner for digital content transformation solutions - Abstracting & Indexing (A&I), Knowledge Modeling (Taxonomies, Thesauri and Ontologies), and Metadata Enrichment & Entity Extraction.Click here to read the original press release.